HIF1A and neoplasm: Compared with ICI monotherapy, the combination of HIF-1-mediated ectoenzyme ENTPD2 inhibitors and ICI (anti-CTLA-4/PD-1) significantly enhanced T cell infiltration into the tumor and extends the survival of tumor-bearing mice [52].